Warning letterPosted May 12, 2026

FDA warning letter to Naveh Pharma LTD/Bigdam Inc.

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

FDA's record ↗

FDA posted a warning letter to Naveh Pharma LTD/Bigdam Inc. on May 12, 2026; the letter is dated May 4, 2026. Subject: CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Issuing office: Center for Drug Evaluation and Research (CDER).

On the record

Company
Naveh Pharma LTD/Bigdam Inc.
Subject
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Issuing office
Center for Drug Evaluation and Research (CDER)
Letter dated
2026-05-04
Posted by FDA
2026-05-12
Source
FDA warning letters ↗

CFR cited

The record cites 2 sections of 21 CFR Parts 201 and 211.

The full record

An account shows the violations FDA described and each CFR section it cited.

What a warning letter is

A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.

More

Watch Naveh Pharma LTD/Bigdam Inc

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA warning letters. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Naveh Pharma LTD/Bigdam Inc.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.